Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Postoperative de novo epilepsy after craniotomy a nationwide register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cyproterone acetate and risk of meningioma: a nationwide cohort study

    Research output: Contribution to journalLetterResearchpeer-review

  3. Understanding the relationship between cognitive performance and function in daily life after traumatic brain injury

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Patient-Centered Treatment of Chronic Migraine With Medication Overuse: More Is Not Always Better

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Reply: The role of neurovascular contact in patients with multiple sclerosis

    Research output: Contribution to journalLetterResearchpeer-review

  3. Health-related quality of life in tension-type headache: a population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jason Charles Ray
  • Mahima Kapoor
  • Richard J Stark
  • Shuu-Jiun Wang
  • Lars Bendtsen
  • Manjit Matharu
  • Elspeth Jane Hutton
View graph of relations

Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.

Original languageEnglish
Article number324674
JournalJournal of neurology, neurosurgery, and psychiatry
Volume92
Issue number12
Pages (from-to)1325-1334
Number of pages10
ISSN0022-3050
DOIs
Publication statusPublished - Dec 2021

    Research areas

  • drug trials, headache, migraine

ID: 62004232